Is Big Pharma squandering its cash on buybacks?

Cash-rich pharma giants have been plowing billions of dollars into stock buybacks, making investors and Wall Street happy. But are buybacks the best use for Big Pharma's cash? Atlas Venture Partner Bruce Booth favors other ways to put those billions to work--ways that could deliver bigger returns in the long run. Report

Suggested Articles

Johnson & Johnson faces a litany of problems, but executives are clearly not concerned—at least not about the company's short-term fortunes.

This week, Goldman Sachs resurrected a burning question: How can pharma companies profit from curing patients with one-time gene and cell therapies?

CMS has determined how it'll pay for Gilead's CAR-T cancer therapy, Yescarta, for outpatient use, but hasn't yet decided on Gilead's…